Aplidin plitidepsin regulatory update

The COMP issued a positive opinion to grant Orphan Drug designation for PharmaMar's Aplidin plitidepsin to treat primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thromboc...